Phase 2A Learnings Incorporated into RewinD-LB, a Phase 2B Clinical Trial of Neflamapimod in Dementia with Lewy Bodies.

J Prev Alzheimers Dis · 2024 · PMC11061005 · PMID 38706271

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

near significanceno p-value reported

In addition, there is significant improvement compared to placebo on ISLT-recognition and near significance for ISLT total score, effects that were not seen in the overall patient population.

also in 167 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.